Press release
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences
LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases,
About this update from Savara, Inc.
[{"type":"text","content":" LANGHORNE, Pa.--(BUSINESS WIRE)--\nSavara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will be presented at the 65th Congress of the German Society of Pneumology (DGP) in Leipzig, Germany taking place April 9-12 and at the 65th Annual Meeting of the Japanese Respiratory Society (JRS) taking place April 11-13, 2025, in Tokyo, Japan.\n\nDGP 2025 Virtual Presentation\n\nPoster Title: Inhaled Molgramostim Improves Pulmonary Gas Exchange, Quality of Life, and Exercise Capacity in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)\nSession: Interstitial Lung Disease, Pulmonary Hypertension, Lung Cancer & Infections\nDate/Time of Poster Discussion Session: April 9, 2025, 14:05 – 14:10 CEST\nPresenter: Francesco Bonella, M.D., Center for Interstitial and Rare Lung Disease, Pneumology Department, Ruhrlandklinik University Hospital, University of Duisburg-Essen, Essen, Germany\n\nFor more information about the 65th Congress of the DGP, please visit their website.\n\nJRS 2025 Poster\n\nPoster Title: Inhaled Molgramostim for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Phase 3 Clinical Trial\nSession: English Poster Discussion “Rare Disease”\nDate/Time of Poster Discussion Session: April 12, 2025, 14:15 – 14:30 JST\nAbstract Number: EPD65\nPoster Number: 65\nPresenter: Yoshikazu Inoue, M.D., Clinical Research Center, NHO Kiniki Chuo Chest Medical Center and Internal Medicine, Osaka Anti-Tuberculosis Association Osaka Fukujuji Hospital, Osaka, Japan\n\nFor more details about the JRS Annual Meeting, please visit their website.\n\nFollowing the sessions, the presentations will be available on the Congresses & Publications page of the Savara corporate website.\n\nAbout Autoimmune Pulmonary Alveolar Proteinosis (aPAP)\naPAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need...